期刊论文详细信息
PLoS One
Efficacy of Oral Metronidazole with Vaginal Clindamycin or Vaginal Probiotic for Bacterial Vaginosis: Randomised Placebo-Controlled Double-Blind Trial
Glenda Fehler1  Deborah De Guingand2  Jane S. Hocking3  Sandra Walker4  Christopher K. Fairley5  Lenka A. Vodstrcil6  Anna N. Morton7  Suzanne M. Garland7  Catriona S. Bradshaw7  Andrea Morrow8  Marie Pirotta8 
[1] Centre for Women's Health, Gender and Society, University of Melbourne, Melbourne, Australia;Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia;Department of General Practice, University of Melbourne, Melbourne, Australia;Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Melbourne, Australia;Department of Microbiology, The Royal Children's Hospital, Melbourne, Australia;Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia;Melbourne School of Population Health, University of Melbourne, Melbourne, Australia;Melbourne Sexual Health Centre, The Alfred Hospital, Melbourne, Australia
关键词: Probiotics;    Bacterial vaginosis;    Antibiotics;    Lactobacillus;    Nurses;    Oral diseases;    Adverse events;    Antifungals;   
DOI  :  10.1371/journal.pone.0034540
学科分类:医学(综合)
来源: Public Library of Science
PDF
【 摘 要 】

Background To determine if oral metronidazole (MTZ-400mg bid) with 2% vaginal clindamycin-cream (Clind) or a Lactobacillus acidophilus vaginal-probiotic containing oestriol (Prob) reduces 6-month bacterial vaginosis (BV) recurrence. Methods Double-blind placebo-controlled parallel-group single-site study with balanced randomization (1∶1∶1) conducted at Melbourne Sexual Health Centre, Australia. Participants with symptomatic BV [Nugent Score (NS) = 7–10 or ≥3 Amsel's criteria and NS = 4–10], were randomly allocated to MTZ-Clind, MTZ-Prob or MTZ-Placebo and assessed at 1,2,3 and 6 months. MTZ and Clind were administered for 7 days and Prob and Placebo for 12 days. Primary outcome was BV recurrence (NS of 7–10) on self-collected vaginal-swabs over 6-months. Cumulative BV recurrence rates were compared between groups by Chi-squared statistics. Kaplan-Meier, log rank and Cox regression analyses were used to compare time until and risk of BV recurrence between groups. Results 450 18–50 year old females were randomized and 408 (91%), equally distributed between groups, provided ≥1 NS post-randomization and were included in analyses; 42 (9%) participants with no post-randomization data were excluded. Six-month retention rates were 78% (n = 351). One-month BV recurrence (NS 7–10) rates were 3.6% (5/140), 6.8% (9/133) and 9.6% (13/135) in the MTZ-Clind, MTZ-Prob and MTZ-Placebo groups respectively, p = 0.13. Hazard ratios (HR) for BV recurrence at one-month, adjusted for adherence to vaginal therapy, were 0.43 (95%CI 0.15–1.22) and 0.75 (95% CI 0.32–1.76) in the MTZ-Clind and MTZ-Prob groups compared to MTZ-Plac respectively. Cumulative 6-month BV recurrence was 28.2%; (95%CI 24.0–32.7%) with no difference between groups, p = 0.82; HRs for 6-month BV recurrence for MTZ-Clind and MTZ-Prob compared to MTZ-Plac, adjusted for adherence to vaginal therapy were 1.09(95% CI = 0.70–1.70) and 1.03(95% CI = 0.65–1.63), respectively. No serious adverse events occurred. Conclusion Combining the recommended first line therapies of oral metronidazole and vaginal clindamycin, or oral metronidazole with an extended-course of a commercially available vaginal-L.acidophilus probiotic, does not reduce BV recurrence. Trial Registration ANZCTR.org.au ACTRN12607000350426.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO201904028136341ZK.pdf 336KB PDF download
  文献评价指标  
  下载次数:6次 浏览次数:5次